Genomic instability in TP53-mutated breast cancer cells treated with etoposide and doxorubicin.

被引：0

作者：

De Vos, ML ^{[1
]}

Weber, BL ^{[1
]}

机构：

[1] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA

来源：

AMERICAN JOURNAL OF HUMAN GENETICS | 2003年 / 73卷 / 05期

关键词：

D O I：

暂无

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

330

引用

页码：226 / 226

页数：1

共 50 条

[1] Genomic landscape of TP53-mutated myeloid malignancies
Abel, Haley J.
Oetjen, Karolyn A.
Miller, Christopher A.
Ramakrishnan, Sai M.
Day, Ryan B.
Helton, Nichole M.
Fronick, Catrina C.
Fulton, Robert S.
Heath, Sharon E.
Tarnawsky, Stefan P.
Srivatsan, Sridhar Nonavinkere
Duncavage, Eric J.
Schroeder, Molly C.
Payton, Jacqueline E.
Spencer, David H.
Walter, Matthew J.
Westervelt, Peter
Dipersio, John F.
Ley, Timothy J.
Link, Daniel C.
BLOOD ADVANCES, 2023, 7 (16) : 4586 - 4598
[2] Clinicopathologic and Genomic Analysis of TP53-Mutated Endometrial Carcinomas
Momeni-Boroujeni, Amir
Dahoud, Wissam
Vanderbilt, Chad M.
Chiang, Sarah
Murali, Rajmohan
Rios-Doria, Eric, V
Alektiar, Kaled M.
Aghajanian, Carol
Abu-Rustum, Nadeem R.
Ladanyi, Marc
Ellenson, Lora H.
Weigelt, Britta
Soslow, Robert A.
CLINICAL CANCER RESEARCH, 2021, 27 (09) : 2613 - 2623
[3] Genomic landscape and prognosis of patients with TP53-mutated non-small cell lung cancer
Fan, Zhisong
Zhang, Qi
Feng, Li
Wang, Long
Zhou, Xinliang
Han, Jing
Li, Dan
Liu, Jiayin
Zhang, Xue
Zuo, Jing
Zou, Xiao
Cai, Yiran
Sun, Ying
Wang, Yudong
ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (04)
[4] Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes
Montalban-Bravo, Guillermo
Kanagal-Shamanna, Rashmi
Benton, Christopher B.
Class, Caleb A.
Chien, Kelly S.
Sasaki, Koji
Naqvi, Kiran
Alvarado, Yesid
Kadia, Tapan M.
Ravandi, Farhad
Daver, Naval
Takahashi, Koichi
Jabbour, Elias
Borthakur, Gautham
Pemmaraju, Naveen
Konopleva, Marina
Soltysiak, Kelly A.
Pierce, Sherry R.
Bueso-Ramos, Carlos E.
Patel, Keyur P.
Kantarjian, Hagop
Garcia-Manero, Guillermo
BLOOD ADVANCES, 2020, 4 (03) : 482 - 495
[5] Patterns of recurrence in surgically treated women for TP53-mutated endometrial carcinomas
Pain, Flore-Anne
Beinse, Guillaume
Azais, Henri
Auvray-Kuentz, Marie
Garcin, Louis-Marie
Delanoy, Nicolas
Bentivegna, Enrica
Benoit, Louise
Nguyen-Xuan, Huyen-Thu
Blons, Helene
Fabiano, Emmanuelle
Belda, Marie-Aude L. E. Frere
Bats, Anne-Sophie
Koual, Meriem
EJSO, 2023, 49 (09):
[6] Somatic Mutations in TP53 Identified in T-Cells of Patients with TP53-mutated AML
Issa, Ghayas C.
Bidikian, Aram
Ayoub, Edward
Wang, Feng
Mohanty, Vakul
Leighton, Jake
Wu, Xiaogang
Patsilevas, Tallie
Alaniz, Zoe
Zarka, Jabra
Kanagal-Shamanna, Rashmi
Daver, Naval
Futreal, Andy
Konopleva, Marina
Navin, Nicholas
Zhang, Jianhua
Chen, Ken
Andreeff, Michael
BLOOD, 2022, 140 : 6267 - 6269
[7] Niclosamide combined to Azacitidine to target TP53-mutated MDS/AML cells
Maslah, Nabih
Rety, Salome
Bonnamy, Melina
Aguinaga, Lorea
Huynh, Tony
Parietti, Veronique
Giraudier, Stephane
Fenaux, Pierre
Cassinat, Bruno
LEUKEMIA, 2024, 38 (07) : 1630 - 1633
[8] FOLFOX resistance in TP53-mutated Metastatic Colorectal Cancer: mechanism and selective targeting
Hollande, Frederic
Behrenbruch, Corina
Foroutan, Momeneh
Simpson, Kaylene
Heriot, Alexander
CANCER SCIENCE, 2023, 114 : 739 - 739
[9] Identification of a rhodium(III) complex as a Wee1 inhibitor against TP53-mutated triple-negative breast cancer cells
Yang, Guan-Jun
Zhong, Hai-Jing
Ko, Chung-Nga
Wong, Suk-Yu
Vellaisamy, Kasipandi
Ye, Min
Ma, Dik-Lung
Leung, Chung-Hang
CHEMICAL COMMUNICATIONS, 2018, 54 (20) : 2463 - 2466
[10] Nutlin-3a Selects for TP53-Mutated Cells in a Fibroblast Immortalisation Assay.
Kucab, J. E.
Taylor, J. K.
Arlt, V. M.
Phillips, D. H.
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2016, 57 : S77 - S77

← 1 2 3 4 5 →